Halozyme Therapeutics (HALO) Total Current Liabilities (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Total Current Liabilities data on file, last reported at $363.2 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $363.2 million, up 141.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $363.2 million (up 141.53% YoY), and the FY2025 annual result was $177.1 million, up 27.31% from the prior year.
• Total Current Liabilities improved to $363.2 million in Q1 2026 per HALO's latest filing, from $177.1 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $837.2 million in Q3 2025 and troughed at $91.9 million in Q1 2023.
• A 5-year average of $186.0 million and a median of $131.6 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities sank 41.66% in 2023, then soared 669.4% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $130.8 million in 2022, then declined by 13.99% to $112.5 million in 2023, then grew by 23.65% to $139.1 million in 2024, then rose by 27.31% to $177.1 million in 2025, then surged by 105.1% to $363.2 million in 2026.
• Business Quant data shows HALO's Total Current Liabilities at $363.2 million in Q1 2026, $177.1 million in Q4 2025, and $837.2 million in Q3 2025.